Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ban on Online Sale of Drugs Runs Counter to the Constitution: JODA
March 23, 2009
- BUSINESS NEWS IN BRIEF
March 23, 2009
- Counterfeit Drugs Will Pour In if Online Sale Is Freed: Ms Tokashiki
March 23, 2009
- Guidance for Biosimilars Issued
March 23, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 23, 2009
- JGA to Improve Its Generics Information Supply System
March 23, 2009
- Why Outsourcing Is the "in" Thing
March 23, 2009
- Savings Notification Services Effective to Promote Use of Generics
March 23, 2009
- Only 30% of Doctors Use Recommended Standard Chemotherapy Regimens
March 23, 2009
- JSGM to Determine Measures to Further Promote Use of Generics
March 23, 2009
- 30% of Asthma Patients Take Oral Steroids: Patient Group Survey
March 23, 2009
- Mr Tsushima Supports NHI Price Maintenance System for New Drugs
March 23, 2009
- 33% of Hospital Pharmacists Write Rx to Change Dosage Form
March 23, 2009
- Materials Derived from Canada-Originated Cow May Be Used without Risk Assessment
March 23, 2009
- Challenges for Pharma Ind. Provide Covance with Unique Opportunity: Mr Barr
March 23, 2009
- REGULATORY NEWS IN BRIEF
March 23, 2009
- SymBio to Apply for Bendamustine in Japan within 2009
March 23, 2009
- Mr Toda Warns Consumers against Counterfeit Drugs Sold Via Internet
March 16, 2009
- Shasun to Enhance Its Presence in Japan via Its Subsidiary in Tokyo
March 16, 2009
- Guidance on Biosimilars Issued by Korosho
March 16, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…